<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474265</url>
  </required_header>
  <id_info>
    <org_study_id>201102-TR</org_study_id>
    <nct_id>NCT01474265</nct_id>
  </id_info>
  <brief_title>Sympathovagal Balance in Smoking Cessation</brief_title>
  <official_title>Alterations in the Autonomic Nervous System During Smoking Quit Attempts- Possible Effects of Pharmacological Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has the following primary aim:&#xD;
&#xD;
      - the main objective of this study is to investigate the effects of smoking cessation during&#xD;
      quit attempts on sympathovagal balance. These effects will be observed in smokers quitting&#xD;
      smoking with pharmacological support or without.&#xD;
&#xD;
      Secondary aims of this study are also:&#xD;
&#xD;
        -  the definition of MSNA in smokers and non-smokers&#xD;
&#xD;
        -  the investigation of other parameters concerning the autonomic nervous system, like&#xD;
           baroreflex-sensitivity, heart rate-variability before and during the quit attempt.&#xD;
&#xD;
        -  the definition of withdrawal symptoms and craving before, during and after the quit&#xD;
           attempt.&#xD;
&#xD;
        -  the investigation of effects of smoking cues on craving and sympathovagal balance&#xD;
&#xD;
        -  the investigation of relapse rates after smoking cessation in correlation with the&#xD;
           parameters mentioned above.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of muscular sympathic nervous activity (MSNA) in bursts / 100 heart beats before and while smoking cessation.</measure>
    <time_frame>33 weeks</time_frame>
    <description>Patients present 7 weeks before their personal smoking-stop-day and participate in the study until week 26 after their personal smoking-stop-day. During that time, MSNA is recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the basal sympathetic nerve activity in smokers compared to never-smokers</measure>
    <time_frame>33 weeks</time_frame>
    <description>first MSNA is carried out 4 weeks before smoking-stop-day (respectively 6 weeks for group D). second and last MSNA is carried out two days after smoking-stop-day (respectively 2 weeks before smoking-stop-day for group D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of craving and withdrawal symptoms during smoking cessation</measure>
    <time_frame>33 weeks</time_frame>
    <description>withdrawal symptoms data is collected by phone calls 3,2,1 days before smoking-stop-day, the day itself and 1 day and 11 (12 for group C and D) weeks after smoking-stop-day.&#xD;
Also the withdrawal symptoms date is collected during each personal examination (means - Pre-Examination, Baseline, Follow I to III).&#xD;
The data will be collected by reliable questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of smoking cues on craving and sympathovagal balance</measure>
    <time_frame>33 weeks</time_frame>
    <description>smoking cues will be presented on the first follow-up-measurement to members of group A-D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of smoking relapse rate</measure>
    <time_frame>33 weeks</time_frame>
    <description>All relapses will be registered to correlate them with the obtained parameters (baroreflex-sensitivity, heartrate-variabilty, MSNA, questionnaires)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>varenicline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette TX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette TX optional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group smokers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>0.5-2 mg per day, oral use</description>
    <arm_group_label>varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1-2 tablets per day, oral use</description>
    <arm_group_label>varenicline placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorette TX</intervention_name>
    <description>10-15 mg per day, transdermal use (patches)</description>
    <arm_group_label>Nicorette TX</arm_group_label>
    <arm_group_label>Nicorette TX optional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and Women at the age of 25 to 60 years.&#xD;
&#xD;
          -  Group A-D: Smokers willing to quit smoking and a FTNA-result &gt;5.&#xD;
&#xD;
          -  Group E: Never-smokers.&#xD;
&#xD;
          -  Signed consent after information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  formerly known hypersensitivity against one of the used pharmacological interventions&#xD;
             or structurally similar drugs or against one of the ingredients.&#xD;
&#xD;
          -  participation in another study during this study or within 4 weeks prior to this&#xD;
             study.&#xD;
&#xD;
          -  Addiction or other circumstances that prevent the patient from estimating the study&#xD;
             and the consequences.&#xD;
&#xD;
          -  Pregnancy and breast-feeding&#xD;
&#xD;
          -  women with childbearing potential, except women that fulfill the following criteria:&#xD;
&#xD;
               -  post menopause&#xD;
&#xD;
               -  postoperative (6 weeks after both-sides ovariectomy with or without hysterectomy)&#xD;
&#xD;
               -  regular and correct use of prevention methods (error-rate &lt;1% a year), e.g.&#xD;
                  implants, depot injections, oral contraceptives, IUP)&#xD;
&#xD;
               -  sexual abstinence&#xD;
&#xD;
          -  signs that predict a possible non-compliance of the patient&#xD;
&#xD;
          -  exclusion because of nicorette tx:&#xD;
&#xD;
               -  psoriasis, dermatitis, urticaria&#xD;
&#xD;
          -  exclusion because of varenicline&#xD;
&#xD;
               -  creatinine-clearance &lt; 30ml/min&#xD;
&#xD;
               -  epilepsy&#xD;
&#xD;
               -  psychiatric diseases (schizophrenia, bipolar disorders, depression).&#xD;
&#xD;
          -  Exclusion because of methods&#xD;
&#xD;
               -  Diseases that increase the sympathetic level (Heart insufficiency, high blood&#xD;
                  pressure (arteria /pulmonary), obstructive sleeping apnoea, COPD)&#xD;
&#xD;
          -  cardiac rhythm disturbances&#xD;
&#xD;
          -  myocardial infarction within the last 8 weeks&#xD;
&#xD;
          -  polyneuropathy&#xD;
&#xD;
          -  diseases that come along with damages of peripheral nerves&#xD;
&#xD;
          -  severe or life-threatening diseases (e.g. cancer with life-expectancy &lt; 5 years,&#xD;
             terminal kidney-insufficiency)&#xD;
&#xD;
          -  treatment with antihypertensive drugs or sympathomimetic substances (e.g.theophyllin)&#xD;
             or smoking cessation medication (NRT, Varenicline)&#xD;
&#xD;
          -  Other reasons, that make a patient not suitable for the study (estimation of primary&#xD;
             investigator)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Raupach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Goettingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 3, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>varenicline</keyword>
  <keyword>sympathovagal balance</keyword>
  <keyword>quit attempts</keyword>
  <keyword>MSNA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

